|Day Low/High||228.23 / 230.83|
|52 Wk Low/High||129.21 / 275.87|
Pockets of speculative trading are narrower, but the appetite for action has not disappeared.
What if areas of expected growth in labor market demand moving forward do not materialize?
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.
Let's check out the LLY charts amid FDA approval of the company's Alzheimer's drug.
This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Let's look at the companies that can go up, and the ones that can't.
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.
I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.
Let's look at this impossible move on the market -- and why health care could be coming off life support.
Let's review the charts and indicators.
This is my fifth worst performing position in a book that contains 62 open positions.
Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.
One of the scary stories deals with what could happen if there was coordinated gaming of the U.S. dollar.
There was a period before the time of commoditization where individual elan and corporate dominance meant something. And that's back.
As power has changed hands in the White House, we can expect these names -- and themes -- to benefit.
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
An executive order says U.S. purchases of military-linked Chinese companies must stop by January 11, including three of the world's top-20 telecoms.
Let's compare several dividend increases in time for the holidays -- and see who wins the 'derby.'
Most important come Inauguration Day is the seamless transition of leadership over 'Operation Warp Speed'.
Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.
Basically, I think we laid out enough reasons for financial markets to revolt, yet they did not.